Gorham-Stout disease (vanishing bone)

Overview

Gorham-Stout disease (GSD) is an exceptionally rare condition where normal bone tissue is gradually destroyed and replaced by an abnormal proliferation of lymphatic vessels, leading to progressive bone loss, also known as osteolysis [PMID:33678096]. It is sometimes called 'vanishing bone disease' due to this characteristic bone disappearance. The condition can affect any bone in the body, but it is more commonly seen in areas such as the ribs, shoulder blade (scapula), pelvis, and spine [PMID:31541819].

GSD typically affects only one part of the body (focal involvement), but in some cases, it can spread to adjacent bones or, more rarely, to multiple, non-contiguous sites. The severity and symptoms of GSD vary widely depending on the location and extent of bone involvement.

Symptoms & clinical features

The symptoms of Gorham-Stout disease often develop gradually and can vary significantly from person to person. Pain in the affected area is a common symptom, sometimes accompanied by swelling. Muscle weakness or a noticeable deformity may also occur as the bone is progressively lost. If a bone in an arm or leg is affected, the limb might appear shorter or weaker.

When GSD affects bones in the chest, such as the ribs or spine, it can lead to serious complications. For example, if the ribs or vertebrae are involved, there may be breathing difficulties or neurological problems if the spinal cord is compressed. Fluid accumulation around the lungs (chylothorax) is a known severe complication that can develop, particularly when chest bones or the diaphragm are affected [PMID:24810626].

Video: Genetics 101

Affected organs

Gorham-Stout disease primarily affects the skeletal system, leading to the destruction of bone tissue in various parts of the body. While any bone can be involved, common sites include the skull, jaw, collarbone (clavicle), shoulder blade, ribs, spine, and pelvis. Long bones of the limbs can also be affected.

Beyond the bones, the abnormal lymphatic vessel growth associated with GSD can sometimes involve adjacent soft tissues. This can lead to complications such as chylothorax, where lymphatic fluid leaks into the space around the lungs, impacting respiratory function. In rare instances, other organs might be indirectly affected due to the proximity of bone destruction or lymphatic involvement.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Gorham-Stout disease is a very rare condition, and its exact prevalence is not well established. It can affect individuals of any age, though it is often diagnosed in children and young adults. The severity of GSD is highly variable; some individuals experience mild, localised bone loss with minimal symptoms, while others face aggressive, widespread destruction and severe complications, particularly if vital structures are involved.

Lifetime risks are difficult to quantify due to the rarity and varied presentation of the condition. Complications like pathological fractures (fractures occurring without significant trauma) are common in affected bones. Serious outcomes, such as chylothorax, can be life-threatening if not managed appropriately. The progression of GSD can be unpredictable, with periods of stability interspersed with active bone loss.

Genetic causes

Unlike many genetic conditions, Gorham-Stout disease is not typically caused by an inherited change in a single gene passed down from parents. Instead, it is considered a somatic or mosaic condition. This means the genetic alterations that lead to the disease occur after conception, within certain cells of the body, rather than being present in every cell from birth.

The precise genetic mechanisms underlying GSD are still under active investigation. Research suggests that changes in genes involved in lymphatic vessel development and regulation may contribute to the uncontrolled growth of these vessels in the bone [PMID:33678096]. However, a specific causative gene has not yet been consistently identified across all cases, indicating complex or diverse underlying molecular pathways.

Inheritance pattern

Gorham-Stout disease has a somatic or mosaic inheritance pattern. This means the genetic changes that cause the condition are not usually inherited from a parent and are not typically passed on to children. Instead, the changes occur spontaneously in some cells during an individual's lifetime, meaning only specific tissues or parts of the body are affected.

Because of this somatic nature, GSD is generally not considered to be hereditary. This differs from conditions caused by germline mutations, which are present in all cells and can be passed through generations. Family members of someone with GSD are generally not at an increased risk of developing the condition themselves.

Diagnosis & testing

Diagnosing Gorham-Stout disease often involves a combination of clinical evaluation, imaging studies, and sometimes a tissue biopsy. X-rays, CT scans, and MRI scans can help to visualise the extent of bone loss and the presence of abnormal lymphatic vessels [PMID:31541819]. A biopsy of the affected bone may be taken to confirm the diagnosis by looking for characteristic abnormal lymphatic vessel proliferation and bone destruction under a microscope.

Genetic testing is not routinely used for primary diagnosis in GSD given its somatic/mosaic nature and the lack of a single, well-established causative gene. Referral to a clinical geneticist may be considered to rule out other rare skeletal conditions with similar features. Within the NHS Genomic Medicine Service, rare bone diseases with complex presentations are typically discussed in multidisciplinary team meetings, and where appropriate, genetic testing via an R-code, such as R21 (inherited disorders of the skeleton), might be considered if there is suspicion of an underlying inherited cause that needs to be excluded.

Management & lifestyle

Managing Gorham-Stout disease is complex and aims to slow disease progression, alleviate symptoms, and prevent complications. Treatment approaches are highly individualised and depend on the affected bones, symptoms, and disease severity. There is no universally effective cure, but various treatments can help manage the condition.

Medical management may include medications such as bisphosphonates to reduce bone resorption, or sirolimus (rapamycin), which targets the lymphatic overgrowth [PMID:24810626]. Radiation therapy can sometimes be used to reduce lymphatic proliferation and bone loss in specific areas. Surgical interventions might be necessary to stabilise bones, remove affected tissue, or manage complications like chylothorax. Regular monitoring through imaging is crucial to track disease progression and adjust treatment plans. Patients with GSD are typically managed by a multidisciplinary team, including orthopaedic surgeons, oncologists, radiologists, and respiratory specialists, often coordinated through rare disease centres within the NHS.

UK care pathway

In the UK, individuals suspected of having a rare skeletal condition like Gorham-Stout disease would typically be referred by their GP to a specialist, such as an orthopaedic surgeon, paediatrician, or geneticist. Further investigations, including advanced imaging, would be arranged. If a genetic cause is suspected, referral to a regional NHS Clinical Genetics service is appropriate. Genetic counsellors play a vital role in explaining potential genetic implications, testing options, and supporting families. While there isn't a specific NHS R-code exclusively for GSD, similar rare bone disorders may fall under R-codes such as R21 (inherited disorders of the skeleton) for diagnostic investigation where other genetic conditions are being considered.

Related conditions

Several other rare conditions can present with features similar to Gorham-Stout disease, making diagnosis challenging. These include other forms of osteolysis like lymphatic malformations or kaposiform lymphangiomatosis, which also involve abnormal lymphatic vessel growth. Maffucci syndrome, which combines multiple enchondromas with vascular anomalies, can also be considered in the differential diagnosis. It is important to distinguish GSD from these conditions as management strategies may differ. A thorough clinical assessment and appropriate investigations are essential for accurate diagnosis.

Frequently asked questions